Qiming Venture Partners and Four Portfolio Companies Win 2025 Sci-Tech Innovation Golden Bull Awards
The "Golden Bull Award" is one of the most influential honors in China's capital markets. The Sci-Tech Innovation Golden Bull Award aims to showcase outstanding listed and unlisted companies in strategic emerging industries, while also recognizing the patient capital that diligently supports the rise of new high-tech enterprises.
The 2025 Sci-Tech Innovation Golden Bull Award winners have been announced. The "Golden Bull Award" is one of the most influential honors in China's capital markets. The Sci-Tech Innovation Golden Bull Awards are designed to accelerate the integration of technological and industrial innovation, serve the real economy, and help China's emerging high-tech industries take critical steps forward.
This year's awards center on technological innovation, focusing on eight strategic emerging industries including next-generation information technology, artificial intelligence, and biomedicine. The program showcases outstanding listed and unlisted companies in these sectors, while also recognizing the patient capital that diligently supports the rise of emerging high-tech enterprises. Qiming Venture Partners and its portfolio companies received multiple honors.
Qiming Venture Partners received the Golden Bull PE/VC Support for Sci-Tech Innovation Award.
Qiming Venture Partners
Won the
Golden Bull PE/VC Support for Sci-Tech Innovation Award
Qiming portfolio company SinoCellTech (688520.SH) received the Golden Bull Listed Company Sci-Tech Innovation Award, while Biren Technology, Sinotau Pharma, and Shenogen Pharma each received the Golden Bull Sci-Tech Enterprise Award.
SinoCellTech
(Biomedicine)
Won the
Golden Bull Listed Company Sci-Tech Innovation Award
Biren Technology
(Artificial Intelligence)
Sinotau Pharma, Shenogen Pharma
(Biomedicine)
Won the
Golden Bull Sci-Tech Enterprise Award
A new wave of technological revolution and industrial transformation is well underway. In recent years, China has focused on strengthening its technological innovation capabilities, actively keeping pace with frontier trends, and as a result has nurtured numerous emerging high-tech industries. Every cutting-edge project in the lab holds massive potential for opening up blue-ocean commercial opportunities. The role of patient capital in this process is crucial. Capital markets are deepening their support for technology companies, with financial resources flowing steadily and precisely to irrigate the fertile soil of innovation.
Source | China Securities Journal
Past Highlights
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming has focused on investing in exceptional early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming's portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.